News
Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform
Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform Integrating Clinical, Cognitive and Functional Assessments onto one device. Durham, NC—December 6, 2018—VeraSci, a global clinical technology and research services company,...
NeuroCog Trials is now VeraSci
Durham, NC—October 12, 2018— NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery....
LEADING ALZHEIMER’S DISEASE SCIENTIST JOINS NEUROCOG TRIALS
DURHAM, NC, July 9, 2018– Specializing in Alzheimer’s Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials...
NeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease
Innovative technology answers the call for improved functional capacity measurements in cognitive disorders Durham, North Carolina, October 30, 2017 -- NeuroCog Trials, Inc. (NCT), the premier global cognition and clinical assessment consulting and technology company,...
FORMER DIRECTOR GENERAL OF THE ITALIAN MEDICINES AGENCY (AIFA) DR. LUCA PANI JOINS NEUROCOG TRIALS
Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and...
NCT Linguistics Sponsors Triangle Biotech Tuesday – Press Release
DURHAM, NORTH CAROLINA, May 19, 2017 NCT Linguistics, a leading global provider of translation, interpretation, and training services, was honored to sponsor Triangle Biotech Tuesday in Research Triangle Park on Tuesday, May 9, 2017. Triangle Biotech Tuesday is a...
NCT Linguistics and NeuroCog Trials Expand Workforce, Office Space At Durham Headquarters
DURHAM, NC, Nov. 30, 2016 — NeuroCog Trials, the leading cognitive services provider for the clinical trials industry, today announced that it is significantly expanding its presence at its headquarters in Durham. Construction is currently underway to give NeuroCog...
NCT Linguistics and Percept Research Announce Partnership – Press Release
NCT Linguistics becomes the exclusive provider of translation services for Percept Research DURHAM, NORTH CAROLINA, October 10, 2016 – NCT Linguistics, the boutique language solutions provider, today announced that it has signed an exclusive agreement with Percept...
Cognitive Dysfunction as a Treatment Target in Depression
NeuroCog Trials welcomes the outcome of the FDA Psychopharmacologic Drug Advisory Committee meeting that cognitive dysfunction in Major Depressive Disorder (MDD) represents an appropriate drug development target. The issue was discussed at the meeting on February 3rd...
NeuroCog Trials, Inc. announces work supporting a major pharmaceutical company clinical trial to assess performance based skills assessment in patients with major depression.
Durham, NC—July 1, 2014— NeuroCog Trials, Inc. announces that it has begun work supporting a major pharmaceutical company clinical trial to assess performance- based skills assessment in patients with major depression. The trial will examine the effects of active drug...